Pfizer

Затворен

СекторЗдравеопазване

26.79

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.4

Максимум

26.91

Ключови измерители

By Trading Economics

Приходи

-2.9B

-238M

Продажби

583M

15B

P/E

Средно за сектора

35.13

57.002

EPS

0.77

Дивидентна доходност

6.43

Марж на печалбата

-1.583

Служители

75,000

EBITDA

-3.8B

1.2B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+6.38% upside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

6.43%

2.22%

Следващи печалби

3.11.2026 г.

Следваща дата на дивидент

1.09.2026 г.

Следваща дата на екс-дивидент

6.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

12B

154B

Предишно отваряне

26.79

Предишно затваряне

26.79

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 23:51 ч. UTC

Pfizer Inc. shares are higher in after-market hours amid broader economic concerns following a reported decline in U.S. retail sales for July.

13.08.2026 г., 23:16 ч. UTC

Pfizer Inc shares are lower in after-market hours following a decline from earlier gains. No specific news was identified to explain the movement.

12.08.2026 г., 23:02 ч. UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

11.08.2026 г., 19:26 ч. UTC

News

Pfizer Inc. shares are lower amid a $44 million settlement over its Chantix drug, which allegedly contained a cancer-linked substance.

10.08.2026 г., 23:01 ч. UTC

Pfizer Inc. shares are lower in after-market hours, continuing a decline since Monday's close amid rising Treasury yields and inflation concerns.

8.08.2026 г., 00:02 ч. UTC

Pfizer Inc shares are lower in after-market hours with no specific news identified. Broader market concerns about interest rate hikes continue to influence sentiment.

7.08.2026 г., 23:01 ч. UTC

Pfizer Inc shares are lower in after-market hours, reaching a session low earlier. No specific news was identified to explain the decline.

6.08.2026 г., 23:51 ч. UTC

Pfizer Inc shares are lower in after-market hours. The decline follows increased crude oil prices and a strengthening U.S. dollar, contributing to market volatility.

5.08.2026 г., 23:02 ч. UTC

Pfizer Inc shares are modestly higher in after-market hours, reaching a session high before pulling back slightly. No specific news was identified for the movement.

4.08.2026 г., 23:21 ч. UTC

Pfizer Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader market sentiment remains positive amid falling crude oil prices.

3.08.2026 г., 23:46 ч. UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

31.07.2026 г., 23:06 ч. UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

30.07.2026 г., 23:26 ч. UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

29.07.2026 г., 23:16 ч. UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

28.07.2026 г., 23:26 ч. UTC

Pfizer Inc shares are lower in after-market hours, reversing an earlier gain. The stock remains above its 20-day moving average.

27.07.2026 г., 18:56 ч. UTC

Pfizer Inc is trading higher, driven by gains in the Pharmaceuticals sub-sector. Shares pulled back earlier in the session from a session high.

24.07.2026 г., 18:06 ч. UTC

Pfizer Inc. shares are lower today, reflecting broader market trends. Earlier, shares fell significantly before partially recovering amid declining crude oil prices.

23.07.2026 г., 09:41 ч. UTC

News

Pfizer Inc. shares are higher in pre-market trading following FDA acceptance of a Priority Review for TALZENNA in combination with XTANDI for prostate cancer.

22.07.2026 г., 23:02 ч. UTC

News

Pfizer Inc. shares are higher in after-market hours following the FDA's acceptance of a Priority Review for TALZENNA and XTANDI in prostate cancer treatment.

21.07.2026 г., 23:11 ч. UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

20.07.2026 г., 23:16 ч. UTC

Pfizer Inc shares are higher in after-market trading, maintaining above their 20-day moving average despite broader market pressures from rising treasury yields.

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

6.38% нагоре

12-месечна прогноза

Среден 28.51 USD  6.38%

Висок 35.75 USD

Нисък 25 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

21 ratings

8

Купи

12

Задържане

1

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat